New Data Presented at the 28th ECTRIMS Congress Showcase Teva Pharmaceutical Industries Limited (TEVA)’s Ongoing Commitment to Multiple Sclerosis Research  
10/8/2012 10:12:08 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that key data from the Company’s multiple sclerosis (MS) franchise will be featured at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13, 2012. Data presentations will provide new insights on COPAXONE® (glatiramer acetate injection), the world’s leading relapsing-remitting multiple sclerosis (RRMS) treatment, and Teva’s investigational oral compound laquinimod, as well as results from the ongoing TOP MS and NARCOMS studies.